KLRC1 and neoplasm: Therefore, the use of specific ICIs that block NKG2A and/or KIRs could enlarge the NK-cell subset capable of fighting MSI CRCs (PD-1+ KIR– NKG2A– plus PD-1+ KIR+ and/or NKG2A+ plus PD-1– KIR+ and/or NKG2A+ NK cells) and could be also effective against MSS CRCs where tumor-associated PD-1+ NK cells are scarce.